A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis

Inclusion Criteria: * Participants fully understand the study, voluntarily participate, and have signed the informed consent form (ICF). * Aged ≥18 years, regardless of gender. * Have a confirmed diagnosis of hepatic fibrosis or cirrhosis based on either: A prior percutaneous liver biopsy (results within 1 year prior to enrollment are acceptable); or Imaging findings (Fibroscan, Fibrotouch, or ultrasound, with results within 3 months prior to enrollment acceptable). * Alanine aminotransferase (ALT) \< 8 × upper limit of normal (ULN). * Female participants of childbearing potential must have a negative serum pregnancy test. Furthermore, the participant or their partner must agree to employ highly effective contraceptive methods from the start of the trial until 6 months after the last dose of the study drug. Exclusion Criteria: * History of major upper gastrointestinal hemorrhage within the past 3 months prior to enrollment, or the presence of gastrointestinal disorders affecting drug absorption at the time of screening. * Total bilirubin (TBIL) \> 3 × upper limit of normal (ULN), or ALT \> 3 × ULN but \< 8 × ULN and TBIL \> 2 × ULN. * Alpha-Fetoprotein (AFP) \> 100 μg/L, even in the absence of clinical indications of hepatocellular carcinoma. * Platelet count (PLT) ≤ 50 × 10⁹/L; Prothrombin activity (PTA) \< 50% or International Normalized Ratio (INR) \> 1.5. * Active bacterial, viral (excluding chronic viral hepatitis B or C), fungal, or parasitic infection within 4 we…